
Aristocrat Leisure (ASX: ALL) delivers strong HY26 growth, expanding margins and cash generation across Gaming, Social Casino and iLottery, positioning the company for sustained earnings momentum and a multi year re rating. With NPATA up 8% (16% in constant currency), EBITDA up 6%, and segment profit expanding in constant currency, ALL has shown an expanding competitive advantage, strong cash generation, and a clear path to sustained NPATA growth.

Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.

Bellevue Gold (ASX: BGL) is lifting production, lowering costs, and generating record free cash flow as higher grade zones come online and hedge commitments fall, positioning the company for a multi year re rating.

Vault Minerals, an ASX-listed mid-tier gold producer, is testing key long-term support after a 2025 peak. Despite strong assets and growth plans, merger uncertainty, weaker guidance, cost pressures, and gold-price sensitivity have weighed on sentiment, while technicals suggest base formation.

Zip Co is recovering from 2026 lows on record earnings, a buyback, and US growth via Stripe. Technically, it broke a downtrend with support near $2.00. Key risks: credit quality, US concentration, and competition.

SRG Global (ASX: SRG) surged after securing $1.85 billion of new contracts, upgrading FY26 EBITDA guidance, and initiating FY27 EBITDA guidance of $190m-$200m. Future performance depends on delivering sustained earnings growth across its diversified infrastructure portfolio.